Breaking News

Andelyn Biosciences Manufactures Viral Vector with AAV Curator Platform

The Adeno-Associated Virus will be used in a Phase 1 trial in patients with advanced, high-risk acute myeloid leukemia.

By: Rachel Klemovitch

Assistant Editor

Andelyn Biosciences, Inc., a patient-focused cell and gene therapy CDMO, has manufactured a viral vector with its AAV Curator Platform for Nationwide Children’s Hospital’s Cellular Therapy and Cancer Immunology Program.  The Adeno-Associated Virus (AAV) will be utilized in a novel cell therapy for Universal-Donor CD38KO CD33CAR-NK cells, to be studied in a clinical trial. The Phase 1 trial will study the safety of the novel therapy in patients with advanced, high-risk acute myeloi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters